Trigemina Receives ISP Approval Of Clinical Study Protocol For TI-001 Phase 2 Trial
The Ruth Group Aaron Estrada (media) firstname.lastname@example.org (646) 536-7028
Trigemina Charles Yeomans (925) 377-0664 email@example.com
SOURCE Trigemina, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts